June 2026 – BIO International Convention, San Diego – Insilico Medicine has announced a groundbreaking collaboration with SK Biopharmaceuticals to accelerate the discovery of novel therapies for neuroimmune disorders using its cutting-edge Pharma.AI platform.
The deal, valued at up to $2.5 billion, includes $18 million in upfront payments and represents one of the largest AI-driven drug discovery partnerships in the Asia-Pacific region. Together, the companies aim to reduce preclinical timelines from 2.5–4 years to just 12–18 months, setting a new benchmark for efficiency in biotech innovation.
SK Biopharmaceuticals brings deep expertise in late-stage development and commercialization, while Insilico contributes its proprietary AI technology for target identification, molecule design, and clinical trial prediction. This collaboration underscores the growing role of AI in drug discovery and highlights the global momentum toward faster, smarter therapeutic development.
Key Developments
- Therapeutic Focus: The partnership targets neuroimmune disorders, including neuroinflammatory, neurodegenerative, and rare neurological conditions – areas with high unmet medical need and historically low success rates.
- Technology Backbone: Insilico’s Pharma.AI platform integrates target validation, generative chemistry, molecule optimization, and clinical trial prediction, enabling rapid end-to-end drug discovery.
- Financials: $18M upfront, with a total potential deal value exceeding $2.5B, plus royalties on net sales -setting a record for APAC AI-biotech collaborations.
- Strategic Fit: SK Biopharmaceuticals contributes late-stage development and commercialization expertise, building on its success with Cenobamate (epilepsy treatment).
- Innovation Impact: Insilico aims to cut preclinical timelines from 2.5–4 years down to 12–18 months, accelerating patient access to therapies.
- Market Reaction: Insilico’s shares rose 5.6% in Hong Kong trading after the announcement, reflecting investor confidence in AI-driven biotech.
Anveta’s Perspective
At Anveta, we believe that AI-enabled drug discovery and global partnerships are key to transforming patient outcomes. This milestone collaboration reflects the same vision we pursue — translating innovative science into differentiated therapies with speed and precision.